Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for ...
BioSpace1d
Novo Makes Case to FDA That Semaglutide Is Too Complex for Compounders to Produce
Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...
FiercePharma1d
Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide
“Novo Nordisk’s aim with this nomination is to ensure that patients receive only FDA-approved, safe, and effective ...
STAT2d
Novo asks FDA to bar compounders from making Ozempic copies
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...
GlobalData on MSN3d
Novo Nordisk plans label expansion for Rybelsus following Phase III win
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 ...